DYN
Conviction 39HealthcareScan · Thu, Sep 24, 2026Dyne Therapeutics, Inc. (DYN) closed at $16.52 (+1.76%) on Sep 24, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 23, RS Rating 68, -38.3% from its 52-week high, -10.7% year to date. Sector: Healthcare · PHARMACEUTICAL PREPARATIONS.
Financials as of Tue, Jun 30, 2026 · quarterly.
Recent news
- Dyne Therapeutics Tumbles As Hot-Streak Rally CoolsTipRanks · Thu, Sep 24, 2026
Congress activity
Disclosed STOCK Act trades in DYN
Insider activity
SEC Form 4 transactions in DYN · open-market 10 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Rhodes Jason P Director · Common Stock · 2026-08-14 | Sell | 1.36M | $34M | 2026-08-14 | 2026-08-17 |
Rhodes Jason P Director · Common Stock · 2026-08-14 | Sell | 478.38K | $12M | 2026-08-14 | 2026-08-17 |
Rhodes Jason P Director · Common Stock · 2026-08-14 | Sell | 322.46K | $8.1M | 2026-08-14 | 2026-08-17 |
Rhodes Jason P Director · Common Stock · 2026-08-13 | Sell | 63.64K | $1.7M | 2026-08-13 | 2026-08-17 |
Lucera Erick Chief Financial Officer · Common Stock · 2026-08-13 | Sell | 1.8K | $47K | 2026-08-13 | 2026-08-17 |
Kerr Douglas Chief Medical Officer · Common Stock · 2026-08-13 | Sell | 1.56K | $41K | 2026-08-13 | 2026-08-17 |
Cox John CEO & President · Common Stock · 2026-08-13 | Sell | 4.99K | $131K | 2026-08-13 | 2026-08-17 |
Friedl-Naderer Johanna Chief Commercial Officer · Common Stock · 2026-08-13 | Sell | 226 | $6K | 2026-08-13 | 2026-08-17 |
Rhodes Jason P Director · Common Stock · 2026-08-13 | Sell | 268.35K | $7.0M | 2026-08-13 | 2026-08-17 |
Rhodes Jason P Director · Common Stock · 2026-08-13 | Sell | 94.42K | $2.5M | 2026-08-13 | 2026-08-17 |
SEC filings
EDGAR filings in DYN · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.
Start free — 14-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.